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Tyrosine Sulfation of Human Antibodies Contributes
to Recognition of the CCR5 Binding Region
of HIV-1 gp120
that closely emulate CCR5 and demonstrate that tyro-
sine sulfation can contribute to the potency and diver-
sity of the human humoral response.
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al., 1994; Zwick et al., 2001). An additional group of HIV-1-infected individual, AC-01, selected for the potent
neutralizing antibodies, whose association with gp120 ELISA response of his serum to the HIV-1 envelope gly-
is enhanced by CD4, has been defined (Thali et al., 1993). coprotein gp120 (Montefiori et al., 2001). Examination of
The epitopes of these CD4-induced (CD4i) antibodies the predicted amino acid sequences of these antibodies
overlap the coreceptor binding region of gp120 (Trkola reveals long heavy chain CDR3 regions rich in acidic
et al., 1996a; Wu et al., 1996). However, the prototypes residues and tyrosines (Figure 1A). Epstein-Barr virus-
of these antibodies, 17b and 48d, are only weakly neu- transformed B cells expressing these antibodies or ex-
tralizing, and thus the usefulness of CD4i antibodies pressing the previously characterized CD4i antibodies
in the control or prevention of HIV-1 infection remains 17b and 48d were metabolically labeled with [35S]-cys-
uncertain (Sullivan et al., 1998; Thali et al., 1993). Pre- teine and -methionine and, in parallel, with [35S]-sulfate.
viously characterized CD4i antibodies, and indeed most Cell supernatants were harvested, immunoprecipitated
neutralizing antibodies described to date, neutralize with Protein A-Sepharose, and analyzed by SDS-PAGE.
T cell line-adapted (TCLA) isolates more potently than Heavy and light chains of all antibodies tested were
primary, clinical isolates (Poignard et al., 2001; Thali et labeled with [35S]-cysteine and -methionine, whereas
al., 1993). only the heavy chains of 47e, 412d, CM51, and E51 were
Of the six antibody complementarity-determining re- labeled with [35S]-sulfate (Figures 1B and 1C). No sulfate
gions (CDRs), the heavy chain CDR3 is the most diverse was incorporated into 48d, which lacks CDR3 tyrosines,
and usually the most functionally important for antigen or 17b, whose CDR3 tyrosines are buried (Kwong et al.,
binding (Alzari et al., 1988). Unlike the CDR1 and CDR2 1998). Full sequence information was obtained for three
domains, which derive directly from the variable-region of the antibodies from subject AC-01 (E51, 47e, and
genes, the heavy chain CDR3 derives primarily from one 412d). These sulfated antibodies were generated from
of 23 functional diversity (D) region genes together with distinct J segments and light chains (data not shown).
one of six joining (J) region genes (Lefranc and Lefranc, We conclude that AC-01 expresses a number of inde-
2001). The junctions bounding the D region are also pendent antibodies whose heavy chains are modified
modified by N and P linked addition. Most D region by sulfate.
genes encode sequences rich in tyrosines. Some of We also investigated single-chain antibody molecules
these sequences—for example, diversity genes 3-9, (scFv) originally selected by phage display from a library
3-22, 4-11, 4-17, and 5-12—are very similar to regions of generated from another HIV-1-infected individual, FDA-2,
proteins known to be tyrosine sulfated, and nine of 23 selected for the potent and broadly neutralizing activity
D genes encode sequences containing one or more tyro- of his serum (Vujcic and Quinnan, 1995). Plasmids en-
sines immediately adjacent to an aspartic acid, a motif coding two of these scFv (C12 and Sb1), along with
present at most sites of tyrosine sulfation (Rosenquist those expressing scFv of 17b and E51, were transfected
and Nicholas, 1993). This apparent bias in D-gene-encod- into 293T cells. Transfected cells were labeled with ei-
ing sequences, combined with the well-documented ther [35S]-cysteine and -methionine or [35S]-sulfate, and
ability of tyrosine sulfation to enhance the affinity of cell supernatants were immunoprecipitated with Protein
receptor-ligand associations (Farzan et al., 1999, 2001; L-Sepharose and analyzed by SDS-PAGE. Figure 1D
Pouyani and Seed, 1995; Preobrazhensky et al., 2000), shows that C12 and Sb1 scFv efficiently incorporated
suggested that this modification might play an integral [35S]-sulfate, as did E51 scFv. As expected, 17b scFv did
role in the human humoral response. not incorporate [35S]-sulfate. Sequencing demonstrated
Here, we demonstrate that human antibodies can be that Sb1 and C12 are formed from distinct J segments
modified in their heavy chain CDR3 regions by function- and light chains, although, strikingly, both derived from
ally important sulfate groups. To our knowledge, these the V1-69 heavy chain, common also to 17b, E51, 47e,
are the first reported examples in which a naturally oc- and 412d. Thus, sulfate-modified antibodies can be
curring posttranslational modification of an antibody readily obtained from at least two individuals with effi-
contributes to its ability to bind antigen. We identify cient humoral responses to HIV-1.
several such antibodies, derived from two HIV-1-infected
individuals chosen for their potently neutralizing anti-
Tyrosine Sulfate Contributes to Antibody Affinitysera (Montefiori et al., 2001; Vujcic and Quinnan, 1995).
We next investigated the location and function of theThe sulfated antibodies from these individuals bind
sulfate moieties on these antibodies. Figure 2 representsgp120 more efficiently in the presence of CD4 and are
schematically the two kinds of immunoprecipitationsspecifically inhibited from binding gp120-CD4 com-
performed in Figures 3 and 4. The scFv derived fromplexes by sulfated peptides based on the CCR5 amino
the sulfated antibody 47e (47e scFv) and a variant ofterminus. Most of these antibodies further emulate CCR5
this scFv in which the first tyrosine of its heavy chainby associating with the gp120 proteins of R5, but not
CDR3 was altered to phenylalanine (Y/F), were charac-X4 HIV-1 isolates, and neutralize these isolates more
terized. As shown in Figure 3A, only 47e scFv and not theefficiently than previously described CD4i antibodies.
Y/F variant could incorporate [35S]-sulfate. We concludeThus, what may be a readily elicitable antibody modifica-
that sulfation of 47e is dependent upon a single tyrosinetion can contribute to the potency and diversity of anti-
in its heavy chain CDR3.bodies that neutralize HIV-1.
Figure 3B demonstrates that the sulfate group present
on 47e scFv is critical to its association with the gp120Results
molecules of one of two primary isolates assayed. [35S]-
cysteine- and -methionine-labeled 47e scFv and its Y/FSulfation of Human Antibodies
variant were incubated with metabolically labeled gp120We initially investigated a set of human monoclonal anti-
bodies (47e, 412d, E51, and CM51) obtained from an of the R5 HIV-1 isolates ADA or YU2, together with unla-
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Figure 2. A Representation of Assays Performed in Figures 3 and 4
Plasmids encoding various scFv were generated and transfected
into 293T cells. Cells were then divided and labeled with [35S]-cys-
teine and -methionine or [35S]-sulfate. Cell supernatants were immu-
noprecipitated with Protein L-Sepharose and analyzed for sulfate
incorporation. Supernatants from [35S]-cysteine- and -methionine-
labeled cells were also incubated with gp120 of various HIV-1 iso-
lates and CD4-Ig and immunoprecipitated with Protein A-Sepharose
to determine association of scFv with CD4-bound gp120.
efficiently precipitated by ADA gp120, whereas only very
inefficient association of the Y/F variant with ADA gp120
was observed. However, both scFv could be efficiently
precipitated by YU2 gp120 bound to CD4-Ig. We con-
clude that the sulfate on 47e contributes substantially
to the ability of this antibody to bind the ADA, but not
the YU2, envelope glycoprotein. Consistent with these
data, we have previously observed that entry of the YU2
isolate is less dependent than that of ADA on sulfate
present at the CCR5 amino terminus (Farzan et al., 1999).
We also investigated the role of sulfate moieties pres-
ent on the 412d antibody using the same approach as
in Figures 3A and 3B. Figure 3C shows that 412d scFv
efficiently incorporated [35S]-sulfate, whereas a variant
of 412d scFv (denoted FF), in which the second and
third tyrosines of its heavy chain CDR3 were altered to
phenylalanines, did not. Figure 3D demonstrates that
412d scFv could be efficiently immunoprecipitated with
CD4-Ig bound to the gp120 molecule of each of three
primary R5 isolates. In contrast, substantially less FF
scFv could be precipitated by these gp120 molecules
bound to CD4-Ig. We conclude that 412d is sulfated
exclusively on tyrosines of its heavy chain CDR3 andFigure 1. Tyrosine Sulfation of Antibodies against the HIV-1 Enve-
lope Glycoprotein that these sulfate groups contribute to the binding of
this antibody to the envelope glycoproteins of at least(A) Heavy chain CDR3 regions and adjacent framework residues of
antibodies characterized in this study, as well as residues 1–19 of three primary HIV-1 isolates. The data in Figures 3A and
CCR5, are shown for comparison. 3C imply that sulfates present on E51, Sb1, and C12 are
(B) Transformed human B cells from HIV-1-infected individuals were also localized exclusively within their heavy chain CDR3
radiolabeled with [35S]-cysteine and -methionine or [35S]-sulfate, as
regions; all the remaining tyrosines present on theseindicated. Supernatants were harvested, precipitated with Protein
antibodies and their adjacent residues are homologousA-Sepharose, and analyzed by SDS-PAGE. Heavy (H) and light (L)
with residues on 47e, 412d, or 17b.antibody chains are indicated.
(C) Additional antibodies from transformed B cell lines, character- To demonstrate a role for tyrosine sulfation of E51 in
ized as in (A). antigen binding, we altered the efficiency of the sulfo-
(D) Single-chain antibody constructs (scFv) prepared from trans- transferase activity in E51 scFv-expressing cells (Figure
formed B cell lines (17b, E51) or selected from a phage-display
4). A plasmid encoding the E51 scFv was cotransfectedlibrary generated from an HIV-1-infected individual with a broadly
into 293T cells with plasmids encoding small hairpinneutralizing serum (C12, Sb1) were radiolabeled as in (B), precipi-
RNA (denoted ST-shRNA in Figure 4) capable of interfer-tated with Protein L-Sepharose, and analyzed by SDS-PAGE.
ing with the message of the two known tyrosyl protein
sulfotransferases (TPST1 and TPST2) (Beisswanger et
al., 1998; Ouyang et al., 1998; Sui et al., 2002). The E51beled CD4-Ig. Protein mixtures were immunoprecipi-
tated with Protein A-Sepharose and analyzed by SDS- scFv-expressing plasmid was also cotransfected with
empty vector or with a plasmid expressing TPST2. CellsPAGE. As shown in Figure 3B, 47e scFv bound and was
Cell
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Figure 4. Sulfation Efficiency Correlates with Affinity of Sulfated
Antibodies for HIV-1 gp120
(A) A plasmid encoding E51 scFv was cotransfected into 293T cells
with a plasmid expressing shRNA complementary to the message
of the two known tyrosyl protein sulfotransferases (ST-shRNA), with
unmodified pcDNA3.1 (vector), or with a plasmid encoding tyrosyl
protein sulfotransferase 2 (TPST2). Transfected cells were divided
and radiolabeled with [35S]-cysteine and -methionine, or [35S]-sulfate,
immunoprecipitated with Protein L-Sepharose, and analyzed by
SDS-PAGE.
(B) Radiolabeled supernatants from [35S]-cysteine- and -methionine-
labeled cells shown in (A) were incubated with CD4-Ig and ADA
gp120, immunoprecipitated with Protein A-Sepharose, and analyzed
Figure 3. Sulfated Tyrosines of the Heavy Chain CDR3 of Anti-gp120 by SDS-PAGE.
Antibodies Contribute to Antibody Affinity (C) Same experiment as in (A), except that 17b scFv is analyzed as
a control.(A) An scFv of 47e was modified by altering the first tyrosine of its
(D) Same experiment as in (B), again using 17b scFv.heavy chain CDR3 to phenylalanine. Plasmids encoding wild-type
(E) Experiment similar to those in (A)–(D) except that two transfec-47e scFv (wt) or this variant (Y/F) were transfected into 293T cells,
tions were performed in sequence. Initially, plasmid encoding ST-which were subsequently radiolabeled with [35S]-cysteine and
shRNA (lane 1), an irrelevant shRNA (lanes 2 and 3), or shRNA vector-methionine, or [35S]-sulfate. Cell supernatants were immunoprecipi-
alone (lanes 4 and 5) was transfected into 293T cells. 24 hr later,tated with Protein L-Sepharose and analyzed by SDS-PAGE.
cells were transfected with plasmid encoding E51 scFv in the pres-(B) Radiolabeled 47e scFv (wt) or its Y/F variant was incubated with
ence (lanes 3 and 5) or absence (lanes 1, 2, and 4) of plasmidCD4-Ig and the gp120 of the primary isolates ADA and YU2, as
encoding TPST2. Cells were divided, radiolabeled with [35S]-cys-indicated. Incubated proteins were immunoprecipitated with Protein
teine- and -methionine (top) or [35S]-sulfate (middle), and superna-A-Sepharose and analyzed by SDS-PAGE.
tants immunoprecipitated and analyzed by SDS-PAGE. Cysteine-(C) The same experiment as in (A), except that a single-chain mole-
and methionine-labeled supernatants were analyzed as in (B) and (C)cule derived from 412d (wt) and a variant of this scFv in which
for association with complexes of CD4-Ig and ADA gp120 (bottom).the second and third tyrosines of the 412d CDR3 were altered to
phenylalanines (FF), were analyzed.
(D) The same experiment as in (B), except that 412d scFv and its
were then divided and radiolabeled with [35S]-cysteineFF variant were analyzed for association with CD4-Ig and gp120 of
and -methionine or [35S]-sulfate. Cell supernatants werethe ADA, YU2, and JR-FL isolates.
harvested and immunoprecipitated with Protein L-Seph-
arose. E51 scFv produced in cells expressing shRNA
targeting TPST1 and TPST2 was much less efficiently
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sulfated than that produced in cells without shRNA
(Figure 4A). An scFv from cells expressing exogenous
TPST2 was substantially more sulfated than that from
cells without exogenous sulfotransferase, implying that
endogenous TPST activity in 293T cells is limiting sul-
fation of overexpressed scFv. The precipitation of the
scFv by ADA gp120 bound to CD4-Ig (Figure 4B) demon-
strates that the E51 scFv associates with ADA gp120 in
direct proportion to the efficiency with which it is sul-
fated. Neither shRNA targeting the tyrosyl sulfotransfer-
ases nor exogenous TPST2 had any effect on the ex-
pression of, or the absence of sulfate incorporation into,
the 17b scFv (Figure 4C), or on its association with gp120
bound to CD4-Ig (Figure 4D). As shown in Figure 4E, an
irrelevant shRNA had no effect on the sulfation of, or
gp120 association with, E51 scFv. These data show that
tyrosine sulfation of E51 contributes to its ability to asso-
ciate with ADA gp120.
Sulfated Antibodies Emulate CCR5
17b and 48d are well-characterized examples of anti-
bodies whose binding to gp120 is enhanced by CD4
(Thali et al., 1993). Figure 5A demonstrates that 47e,
412d, E51, Sb1, and C12 are also CD4i antibodies. scFv
of these antibodies and of 17b were immunoprecipitated
with Protein L-Sepharose together with ADA gp120 in
the presence or absence of soluble CD4. Except for
E51 scFv, binding of each scFv to gp120 was at least
doubled by soluble CD4. Binding of E51 scFv to gp120
was increased by approximately 25% in the presence
of CD4.
To define the relationship between the epitope of
these antibodies and the CCR5 binding site of gp120,
sulfated peptides corresponding in sequence to the
CCR5 amino terminus were tested for their ability to
compete with these antibodies for gp120-CD4 com-
plexes. The CD4i antibody 412d or the antibody 2G12
was incubated with soluble CD4 and radiolabeled ADA
gp120 in the presence or absence of s22, a CCR5-
Figure 5. Tyrosine-Sulfated Antibodies Mimic CCR5
derived peptide sulfated at tyrosines 10 and 14 that
(A) Radiolabeled scFv were incubated with radiolabeled gp120 ofhas been shown to block the association of gp120-CD4 the ADA isolate in the presence or absence of soluble CD4. Protein
complexes with CCR5 (Farzan et al., 2000; Cormier et mixtures were immunoprecipitated with Protein L-Sepharose and
al., 2000). As shown in Figure 5B, s22 partially inhibited analyzed by SDS-PAGE. Ratios of gp120 precipitated in the pres-
precipitation of gp120 by 412d, but not by 2G12, which ence or absence of soluble CD4 were calculated by densitometry.
Error bars indicate the range of results of two or more experiments.binds a glycosylated epitope distinct from the CCR5
(B) Radiolabeled ADA gp120 was incubated with soluble CD4 andbinding domain (Trkola et al., 1996b).
the indicated antibodies in the presence or absence of s22, a peptideWe then assayed the ability of s22 and other peptides
derived from the first 22 residues of the CCR5 amino terminus in
previously characterized for their ability to block the which tyrosines 10 and 14 are sulfated. ADA gp120 was immunopre-
association of gp120-CD4 complexes with CCR5 to in- cipitated by Protein A-Sepharose and analyzed by SDS-PAGE.
hibit association of gp120 with the scFv of sulfated anti- (C) Radiolabeled scFv was incubated with ADA gp120 and CD4-Ig
bodies (Farzan et al., 2000). Each scFv was incubated in the presence of peptide buffer (buffer only), an unsulfated peptide
derived from the first 22 residues of the CCR5 amino-terminus (c22),with ADA gp120 and CD4-Ig, as in Figures 3B and 3D.
s22, or a peptide derived from residues 7–28 of the C5a receptorPeptides were added to each mixture of scFv, ADA
sulfated at the tyrosines corresponding to residues 11 and 14 of thatgp120, and CD4-Ig. As shown in Figure 5C, neither an
receptor (c5aR-s22). Protein and peptide mixtures were immunopre-
unsulfated peptide derived from the 22 amino-terminal cipitated with Protein A-Sepharose and analyzed by SDS-PAGE.
residues of CCR5 (c22) nor a doubly sulfated peptide
based on the amino terminus of the C5a receptor (c5aR-
We further investigated the degree to which theses22) significantly affected association of any of the scFv
sulfated antibodies replicate properties of CCR5. E51,with CD4-Ig bound ADA gp120. However, s22 inhibited
C12, 412d, Sb1, and 17b scFv were incubated with CD4-association of each scFv with ADA gp120-CD4-Ig com-
Ig and gp120 of the primary R5 isolates ADA, YU2, orplexes. The data of Figure 5 imply that 47e, 412d, E51,
JR-FL, or of the laboratory-adapted X4 isolate HXBc2,Sb1, and C12 bind a CD4-enhanced epitope of gp120
immunoprecipitated with Protein A-Sepharose, and an-that overlaps with the binding domain of the CCR5 amino
terminus. alyzed by SDS-PAGE. Each single-chain antibody effi-
Cell
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Figure 6. Sulfated Antibodies Preferentially Associate with gp120 of Isolates that Use CCR5
(A) Radiolabeled gp120 of R5 isolates ADA, YU2, or JR-FL, or of the X4 isolate HXBc2, were incubated with CD4-Ig and radiolabeled scFv of
the indicated CD4i antibodies or of the CD4 binding site antibody b12. Protein mixtures were then immunoprecipitated with Protein A-Sepharose
and analyzed by SDS-PAGE.
(B) Radiolabeled gp120 of the indicated isolates was incubated with CD4-Ig and radiolabeled scFv of 412d. Protein mixtures were analyzed
as in (A). gp120 molecules are grouped according to their coreceptor usage, with R5 indicating CCR5-usage, R5X4 indicating usage of both CCR5
and CXCR4, and X4 indicating usage of CXCR4. All isolates belong to clade B except SA32, MCGP1, and SG3 (clade C), and ELI (clade D).
ciently bound the gp120 of all R5 isolates, but only the with the inability of this variant to bind ADA gp120, as
shown in Figure 3D.17b and, unexpectedly, the E51 scFv bound gp120 of
the X4 isolate HXBc2 (Figure 6A). We then characterized Figure 7C shows a pattern of preferential neutraliza-
tion of R5 isolates by sulfated antibodies similar to thatthe range of envelope glycoproteins recognized by
412d. As shown in Figure 6B, 412d scFv bound the in Figure 7A. Both 412d and E51 neutralized the ADA
virus more efficiently than did 17b. 412d neutralized thegp120 of all R5 isolates examined, including the clade
C isolate SA32 and three clade B isolates. It also bound ADA virus comparably to F105, with EC50s of roughly
0.5 g/ml, whereas the EC50 of E51 was substantiallythe gp120 of the clade B R5X4 isolate 89.6, but not that
of the clade C R5X4 isolate MCGP1. 412d scFv did not less than 0.05 g/ml. The EC50 for 17b was greater than
2 g/ml. E51 and 412d were more efficient than 17b andassociate with the gp120 of any X4 isolate, including
the clade B isolates HXBc2 and MN, the clade C isolate F105 at neutralizing the primary R5X4 isolate 89.6. In
contrast, F105 was more efficient at neutralizing the X4SG3, and the clade D isolate ELI. Thus, 412d preferen-
tially binds gp120 of a range of R5 isolates, but not that isolate HXBc2 than was 17b or E51. Again, 412d did
not neutralize HXBc2. No antibody assayed neutralizedof any X4 isolate assayed.
HIV-1 pseudotyped with the envelope glycoprotein of
the amphotrophic murine leukemia virus (A-MLV). These
Neutralization of Primary HIV-1 Isolates data demonstrate that 412d and E51 neutralize primary
Finally, we compared the antibodies E51 and 412d with R5 and R5X4 isolates more efficiently than the previously
17b, 48d, and a well-characterized CD4 binding site characterized CD4i antibodies 17b and 48d, but are less
antibody, F105, for their ability to neutralize HIV-1 pseu- able to neutralize an X4 isolate than are the latter unsul-
dotyped with various envelope glycoproteins (Posner fated antibodies.
et al., 1993). Figure 7A shows that 48d neutralized the
laboratory-adapted virus HXBc2 but was much less effi-
cient at neutralizing the primary R5 virus ADA. In con- Discussion
trast, 412d efficiently neutralized the ADA, but not the
HXBc2, virus. The 412d scFv was more than ten times Here, we describe a subset of anti-gp120 antibodies
with properties distinct from any thus far characterized.as potent as full-length 412d antibody (Figures 7A and
7B) at neutralizing ADA virus. No neutralization was ob- This subset belongs to the group of CD4i antibodies for
which 17b and 48d are prototypes (Thali et al., 1993).served with the 412d-FF variant (Figure 7B), consistent
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Figure 7. Sulfated Antibodies Efficiently Neutralize Primary HIV-1 Isolates
(A) Luciferase-expressing HIV-1 pseudotyped with the envelope glycoprotein of the R5 isolate ADA (open squares and diamonds) or the X4
isolate HXBc2 (closed squares and diamonds) was incubated with the indicated concentrations of 412d antibody (squares) or 48d (diamonds)
and Cf2Th cells stably expressing CD4 and CCR5 (ADA infection) or CXCR4 (HXBc2 infection). Cells were washed after 1 hr, and luciferase
activity measured. Values are expressed as percent infection in the absence of antibody.
(B) Experiment similar to (A) except that the 412d scFv (open squares) is compared to a variant (412d-FF scFv; closed squares) in which the
second and third tyrosines of its CDR3 region are altered to phenylalanines for ability to neutralize virus pseudotyped with envelope glycoprotein
of the ADA isolate.
(C) Experiment similar to (A) except that virus pseudotyped with the envelope glycoproteins of the R5 isolate ADA, the R5X4 isolate 89.6, or
the X4 isolate HXBc2, or of the amphotrophic murine leukemia virus (A-MLV) was assayed in the presence of the indicated concentrations of
the CD4 binding-site antibody F105 (circles), or the CD4i antibodies 17b (diamonds), 412d (squares), or E51 (triangles). Leftmost points
represent results without antibody. Figures show representative experiments of two (A) or three (B) performed with similar results.
Like 17b and 48d, the antibodies described here bind other means remains to be investigated. Our data sug-
gest that sulfated CD4i antibodies neutralize primarya gp120 epitope exposed or formed by CD4. Unlike
17b and 48d, most of these antibodies preferentially viruses more potently than the prototypical CD4i anti-
bodies 17b and 48d. Given the conservation of much ofassociate with, and efficiently neutralize, primary R5 iso-
lates, and, most interestingly, are modified in their heavy the gp120 CCR5 binding domain, these observations
suggest that eliciting antibodies that bind this epitopechain CDR3 by tyrosine sulfation, the same modification
present on CCR5. As in the case of CCR5, these sulfate may be more useful than has been appreciated (Rizzuto
et al., 1998).moieties contribute to antibody association with gp120.
Moreover, the epitope of these antibodies significantly This study also sheds some light on the characteris-
tics of antibodies that bind the CCR5 binding domainoverlaps the region of gp120 that binds the sulfated
CCR5 amino terminus. Thus, HIV-1 infection can induce and on heavy chain genes that contribute to the likeli-
hood of sulfation. One striking observation is that all thethe production of soluble surrogates for CCR5 that func-
tion as dominant-negative inhibitors of gp120-corecep- sulfated antibodies, and also 17b, obtained from a total
of three individuals, originate from a common VH gene,tor engagement.
As noted, sulfated antibodies were obtained from two V1-69. It is unlikely, however, that V1-69 predisposes
an antibody toward sulfation, as both sulfated and un-individuals with potent anti-gp120 activity in their sera
(Montefiori et al., 2001; Vujcic and Quinnan, 1995). The sulfated CD4i antibodies derive from this gene. How-
ever, the heavy chain CDR3 of three of five sulfatedpresence of tyrosine-sulfated anti-gp120 antibodies
may therefore in some cases be associated with longer- antibodies (47e, E51, and Sb1) derives from JH6, one of
six heavy chain joining genes. This use of JH6 may reflectterm control of HIV-1. Whether sulfated antibodies them-
selves contribute to long-term control or are simply a the fact that it encodes five sequential tyrosines at its
5 end and also that it is the longest of the J genes,product of a healthy humoral response preserved by
Cell
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Unbound phages were recovered by centrifugation at 4C and thenresulting in a longer CDR3. A longer CDR3 may be more
incubated with Protein G beads bound to a soluble trimeric complexaccessible to the tyrosyl protein sulfotransferases and
of the HXBc2 HIV-1 envelope glycoprotein. Beads were washed andmay enable CD4i antibodies to bypass gp120 variable
phage eluted by incubation with a 0.1 M HCl-glycine solution (pH
loops adjacent to the conserved epitope of these anti- 2.2). XL1-Blue E. coli cells were reinfected and panning repeated
bodies (Kwong et al., 1998; Wyatt et al., 1998). Most of for five rounds. Phagemid DNA was isolated from the panned library,
digested with SpeI and NheI to remove the gene III fragment, andthe sulfated tyrosines identified in this study appear in
self-religated (Moulard et al., 2002). Fab molecules of individualsequences encoded by diversity genes or contributed
clones were screened by ELISA for ability to bind HXBc2 gp120.by N- or P-linked addition. For example, it is likely that
both 412d and E51 arose from recombinations that in-
Generation of Single-Chain Antibody Moleculesclude the diversity gene 4-17, which contains the DYXDY
Primers based on consensus sequences of heavy and light variable
pattern found at the CDR3 of both antibodies. The diver- regions were used separately to PCR-amplify heavy and light chain
sity gene origins of other sulfated antibodies are less variable regions of F105, 17b, 47e, 412d, and E51, using cDNA made
from total RNA of transformed B cells expressing these antibodies.obvious, but D genes 3-22 (encoding YYYDSSGYYY),
PCR fragments from these variable regions were ligated into a plas-5-12 (encoding GYSGYDY), or 4-4 or 4-11 (both encoding
mid expressing the leader sequence of CD5. Heavy and light chainsDYSNY) may have contributed to the formation of one or
were connected by a sequence encoding a 12 amino acid linkermore of these antibodies (Lefranc and Lefranc, 2001).
(GGGSGGGSGGGS). Similar single-chain molecules of Sb1 and C12
It has become increasingly apparent that tyrosine sul- were generated by PCR-amplification of Fab-expressing plasmids
fation, once thought an infrequent modification, plays a obtained by phage-display selection. Tyrosine-to-phenylalanine
variants of these scFv were generated by the QuikChange methodcommon and important role in the binding of many li-
(Stratagene).gands to their receptors. The presence of functional
sulfate groups at the ligand binding domains of —among
Labeling and Immunoprecipitation of Antibodies and scFvmany others—PSGL-1, the C5a receptor, and many or
Immunoprecipitation of protein from B cell lines or from 293T cells
all chemokine receptors implies that tyrosine-sulfate transfected by the calcium phosphate method with plasmids encod-
groups can enhance the affinity of protein associations ing single-chain antibody molecules was performed as previously
(Farzan et al., 2002a, 1999, 2001; Pouyani and Seed, described (Farzan et al., 1999). Briefly, cells were divided and incu-
bated for 24 hr in cysteine- and methionine-free DMEM (Sigma) with1995; Preobrazhensky et al., 2000). It is therefore per-
[35S]-cysteine and -methionine or in sulfate-free media (ICN) withhaps not surprising that the humoral immune response,
[35S]-sulfate. Supernatants were harvested. Full-length antibody wasselected for its ability to bind antigen efficiently, would
immunoprecipitated with Protein A-Sepharose (Pharmacia), and
utilize sulfated tyrosines. The heavy chain CDR3 is the scFv were immunoprecipitated with Protein L-Sepharose (Pierce).
most diverse and commonly the most important antigen [35S]-cysteine- and -methionine-labeled scFv were also immunopre-
binding region of antibodies; immunoglobulin diversity cipitated with Protein A-Sepharose after incubating cell superna-
tants with CD4-Ig and radiolabeled gp120 from various HIV-1 iso-genes are the most direct means by which the genome
lates at 37C for 30 min. Protein mixtures were then analyzed bycan bias the sequence of the heavy chain CDR3. Se-
SDS-PAGE.quences encoded by these genes reflect evolutionary
pressure toward high-affinity associations and, in sev-
Modulation of scFv Sulfation by RNA Interference and TPST2
eral cases, are homologous with regions of proteins In order to decrease sulfation of scFv, a plasmid encoding E51 scFv
shown to be tyrosine sulfated (Rosenquist and Nicholas, was cotransfected into 293T cells with plasmids encoding small
1993). In light of these sequences and the data pre- hairpin RNA (shRNA) targeting tyrosyl protein sulfotransferases 1
and 2 (TPST1 and TPST2), under the control of the murine U6 pro-sented here, it is possible that antibody sulfation con-
moter (Sui et al., 2002). Sense-strand target sequences of the TPST1tributes to the humoral response to pathogens other
and TPST2 messages were GGGCCATGCTGGACGCACATC andthan HIV-1.
GGGACAGCAGGTGCTAGAGTG, respectively. A nine-nucleotide
loop sequence (TTCGATAGA) connects the sense and anti-sense
Experimental Procedures strands of the hairpin structure. Separately, E51 scFv-expressing
plasmid was cotransfected with plasmid encoding TPST2 to en-
Antibodies hance sulfation, or with pcDNA3.1 vector alone.
Hybridomas secreting human monoclonal antibodies 17b and 48d
have been previously described (Thali et al., 1993). B cell lines secre- Peptide Inhibition of scFv Association with gp120
ting the human monoclonal antibodies E51, CM51, 412d, and 47e In some cases, scFv immunoprecipitation was performed in the
were derived by Epstein-Barr virus (EBV) transformation of B cells presence of CCR5- or C5a-receptor-derived peptide (Farzan et al.,
from cryopreserved peripheral blood mononuclear cells (PBMC) of 2001, 2000). In these cases, 200 M of peptide resuspended in
an HIV-1-infected subject, AC-01 (Montefiori et al., 2001). Proce- phosphate-buffered saline (PBS) or PBS alone and was incubated
dures for generation of these antibodies have been described (Xiang at 37C with CD4-Ig and gp120 of the ADA HIV-1 isolate. scFv and
et al., 2002). Briefly, supernatants from EBV-inoculated PBMC cul- Protein A-Sepharose were subsequently added at room temperature
tures were screened for IgG antibodies binding to HIV-1 envelope and immunoprecipitated as described above. Peptides assayed
glycoproteins, using a previously described “reverse capture” im- were s22, corresponding to residues 1–22 of CCR5 (MDYQVSSPIY
munoassay. Antibody-producing cultures were cloned and assayed DINYYTSEPAQK; underlined tyrosines are sulfated), c22 (identical
for ability to compete with the prototypical CD4i antibodies 17b and to s22 except that none of its tyrosines is sulfated), or c5aR-s22
48d for gp120 binding. The antibody F105 (Posner et al., 1991) was (TTPDYGHYDDKDTLDLNTPVKD, sulfated at both tyrosines) corre-
a generous gift of Marshall Posner (Beth Israel Deaconess Medical sponding to residues 7–28 of the C5a receptor.
Center).
CD4 Enhancement of Antibody Binding to gp120
Radiolabeled gp120 of the ADA isolate was incubated with scFv inPhage Selection of Antibody Fab Molecules
A Fab phage library was prepared from the bone-marrow RNA of an the presence or absence of soluble CD4. scFv and gp120 were
immunoprecipitated with Protein L-Sepharose and analyzed byHIV-1-infected individual (FDA-2), as described previously (Parren et
al., 1998; Vujcic and Quinnan, 1995; Zwick et al., 2001). Phages SDS-PAGE. Ratios of gp120 precipitated in the presence or absence
of CD4 were measured by densitometry.were preabsorbed on Protein G beads in PBS containing 1% BSA.
Tyrosine Sulfation of Antibodies
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Neutralization of HIV-1 Infection tropic primary HIV-1 isolate that uses fusin and the -chemokine
receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85,Single-round infection of a luciferase-expressing HIV-1 vector has
been described (Wojtowicz et al., 2002). Briefly, luminometer-com- 1149–1158.
patible 96-well tissue-culture plates were seeded with 6 103 Cf2Th- Doranz, B.J., Lu, Z.H., Rucker, J., Zhang, T.Y., Sharron, M., Cen,
CD4-CCR5 or Cf2Th-CD4-CXCR4 cells per well. Cell media were Y.H., Wang, Z.X., Guo, H.H., Du, J.G., Accavitti, M.A., et al. (1997).
removed, and cells incubated with approximately 10,000 cpm units Two distinct CCR5 domains can mediate coreceptor usage by hu-
per ml of reverse transcriptase activity of HIV-1-luciferase virus man immunodeficiency virus type 1. J. Virol. 71, 6305–6314.
pseudotyped with envelope glycoproteins of the ADA, HXBc2, or
Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y., Naga-
89.6 HIV-1 isolates, or with envelope glycoprotein of the ampho-
shima, K.A., Cayanan, C., Maddon, P.J., Koup, R.A., Moore, J.P.,
trophic murine leukemia virus, in the presence of varying concentra-
and Paxton, W.A. (1996). HIV-1 entry into CD4 cells is mediated
tions of the purified antibodies. Luciferase activity was measured
by the chemokine receptor CC-CKR-5. Nature 381, 667–673.
at 60 hr postinfection. Antibodies used in these experiments were
Earl, P.L., Doms, R.W., and Moss, B. (1990). Oligomeric structurepurified from transformed B cells expressing 17b, 48d, F105, 412d,
of the human immunodeficiency virus type 1 envelope glycoprotein.and E51, and quantified by Coomassie staining of SDS-PAGE-ana-
Proc. Natl. Acad. Sci. USA 87, 648–652.lyzed protein.
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